CA2638270A1 - Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib - Google Patents

Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib Download PDF

Info

Publication number
CA2638270A1
CA2638270A1 CA 2638270 CA2638270A CA2638270A1 CA 2638270 A1 CA2638270 A1 CA 2638270A1 CA 2638270 CA2638270 CA 2638270 CA 2638270 A CA2638270 A CA 2638270A CA 2638270 A1 CA2638270 A1 CA 2638270A1
Authority
CA
Canada
Prior art keywords
imatinib
combination
compound
bcr
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2638270
Other languages
English (en)
Inventor
Enrico Pesenti
Dario Ballinari
Jurgen Moll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA 2638270 priority Critical patent/CA2638270A1/fr
Publication of CA2638270A1 publication Critical patent/CA2638270A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2638270 2008-07-24 2008-07-24 Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib Abandoned CA2638270A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2638270 CA2638270A1 (fr) 2008-07-24 2008-07-24 Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2638270 CA2638270A1 (fr) 2008-07-24 2008-07-24 Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib

Publications (1)

Publication Number Publication Date
CA2638270A1 true CA2638270A1 (fr) 2010-01-24

Family

ID=41611006

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2638270 Abandoned CA2638270A1 (fr) 2008-07-24 2008-07-24 Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib

Country Status (1)

Country Link
CA (1) CA2638270A1 (fr)

Similar Documents

Publication Publication Date Title
EP2320903B1 (fr) COMBINAISON THÉRAPEUTIQUE CONTENANT UN INHIBITEUR DE CDKs ET UN AGENT ANTINÉOPLASTIQUE
US8927530B2 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
EP2501385B1 (fr) Combinaison therapeutique comprenant un inhibiteur cdc7 et un agent antineoplastique
AU2014282798A1 (en) Pharmaceutical combinations
US20210030718A1 (en) Combinations for treating cancer
CA2987340C (fr) Polytherapie a base de pac-1
AU2015266552A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
US20100022553A1 (en) Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
CA2638270A1 (fr) Combinaison therapeutique comprenant un inhibiteur d'aurora kinase et imatinib
EP2344156B1 (fr) Combinaison thérapeutique composée d un inhibiteur de kinase aurora et d un agent antinéoplasique
JP2010523470A (ja) 抗癌化合物の投与方法
EP2313097B1 (fr) Combinaison thérapeutique renfermant un inhibiteur de la kinase aurora et des agents antiprolifératifs
TW201924721A (zh) 包含pi3激酶抑制劑與bcl-2抑制劑的組成物
Yim Malt Signaling

Legal Events

Date Code Title Description
FZDE Dead